A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tuberculosis-vaccine-Archivel-Farma (Primary) ; Sodium chloride
Indications Tuberculosis
Focus Pharmacodynamics
Acronyms RUTIVAC-1
Sponsors Archivel Farma

Most Recent Events

20 Mar 2023 Status changed from active, no longer recruiting to completed.
27 Apr 2020 Status changed from recruiting to active, no longer recruiting.
30 Oct 2019 Planned End Date changed from 31 Mar 2024 to 1 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight